The FDA has approved the first cancer therapy biosimilar in the United States, a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer, including colorectal, lung, brain, kidney, and cervical cancers.
The FDA has approved dabrafenib in combination with trametinib for the treatment of BRAF V600E mutated non-small cell lung cancer.
The FDA has approval pembrolizumab (Keytruda), in combination with chemotherapy, for the first-line treatment of patients with metastatic non-squamous non–small-cell lung cancer.
The addition of selumetinib to docetaxel failed to improve progression-free and overall survival in patients with KRAS-mutated locally advanced or metastatic NSCLC.
The use of the PD1 inhibitor nivolumab appeared to be feasible and safe in a small study of patients with untreated, stage I–IIIa non–small-cell lung cancer.
The FGFR inhibitor dovitinib showed modest efficacy in a phase II trial of patients with pretreated, advanced squamous cell lung cancer with FGFR1 amplification
An antibody-drug conjugate, rovalpituzumab tesirine, shows promising efficacy against recurrent small-cell lung cancer.
Matching targeted therapies to genetic abnormalities harbored by tumor types for which those therapies are not approved by the FDA might expand treatment options for some patients with advanced cancers.
First-line osimertinib, a targeted therapy against EGFR mutations, was found to be effective in patients with advanced non–small-cell lung cancer, resulting in a 77% overall response rate.
New data indicates that entrectinib has clinical activity in patients with a variety of cancers with gene alterations in NTRK1/2/3, ROS1, or ALK who had never been treated with targeted agents.